

Advances in Adoptive Cellular Therapy with special reference to Chimeric Antigen Receptor: An Overview



Mughisa Nagori*, Sakshi Aole, Garvita Joshi, Akanksha Jagwani

Mahakal Institute of Pharmaceutical Studies, Ujjain, Madhya Pradesh, 456664

mughisa.16aug@gmail.com

Abstract

Adoptive Cellular Therapy is a potentially progressive therapy for the treatment of different types of cancers. Recently, three therapies are in considerations for the approval by the FDA; they are Tumor- Infiltrating Lymphocytes (TILs), Chimeric Antigen Receptor (CAR) and T-Cell receptor engineered T cells. Immunotherapy when taken in consideration with engineered T cell is effective have a distinct role in the cessation of cancerous cells. CAR basically finds use which grafts the immune system cells to typically T cell to target its function. It has in the T cell activator domain that to induce specificity for the target cell. These approaches can create a widespread use for the treatment of malignancies when taken into consideration.

Keywords: Adoptive Cell Therapy, Chimeric Antigen Response, Tumor- Infiltrating Lymphocytes, Cancer, T cell

Tumor Infiltrating Lymphocyte (TIL):

In recent years, the Adoptive Cell Therapy (ACT) has been a topic of discussion in the area of immunology where it has a diverse application in the stages of blood cancers [1]. Majorly, T cells from the peripheral blood stream are withdrawn to genetically modify the sequencing and express the new receptor as transgenic receptor which is now well understood as TIC [2]. Studies show that adoptive transfer of T cells has least differentiated phenotypes, memory cells and effector T cells. Although it is crucial for the treatment of leukemia to a considerable extent. It also withstands the memory response which is mediated by CD45RO gene in human race. [3]This gene is associated with the secondary lymphoid tissue and thus mediates the memory response, though they are examples of least differentiated memory cells like other T cell subtypes. Sometimes, T cells fail to respond to the progressive cancer and chronic infections, this produces a delayed response in the treatment of cancerous tumors [4–6]. Though human bodies predominantly have T cells which targets the cancerous cells, and thus are considered a boon in immunology. A hinderance to this mechanism arises when these T cells are bound to first get activated which would then target the cancerous cells. This roadblock takes a lot of time to induce the immune system thereby delaying the natural therapy. This form of Adoptive Cell Therapy (ACT) is called Tumor Infiltrating Lymphocytes (TIL)

that finds its importance when already activated T cells are withdrawn from the naturally occurring body part and then is infused into the patient with the same problem. (Fig. 1) This helps in cutting short of the time to get activation thereby decreasing the time of action of T cells [5].




Fig 1: Mechanism of TIL

Engineered TCR (T Cell Receptor) Therapy:

Initially, from melanoma patients, the TILs isolated, showed two mutant melanocytes, MART-1 and gp100. These two genes had expressed themselves in the regions of eyes, ear and skin. But this was of great help that either of the genes did not show a toxic response when treated with TIL therapy. This paved a way for upcoming developments in the fields of TCR. With the introduction to TCR, a boon in the immunological science was made to come into account. Not every patient has their T cells activated, and for such patients, engineered T cell therapy is considered. In this, unlike the former one, the cells are extracted from the tumor inducing body and then are engineered with a new T cell that will now target the specific cancerous cell. This is a very potent technique which is now being used to a comparatively good extent and hence able to save life from a deadly disease. The mechanism behind this therapy is modification of alpha and beta chains of TCR to enhance their stability and reducing of mispairing. Moreover, TCRs have more affinity towards the tumor causing gene and easily recognizes the extracellular targets. This technique had its cons though, like it was a very difficult task to isolate a specific T cell from the cancerous cells, but clinical studies showed a significant rise in the treatment approaches by this method. (Fig. 2) Furthermore, the naïve cells undergo a multiplicative expansion to 10-20 folds after activating by the TCR. After being amplified, the activated receptors participate in the signal transduction in the plasma membrane. This transduction progresses with the channeling of calcium binding proteins, which triggers the nuclear factor of T cells [7,8]




Fig 2: TCR Engineered Cells

CAR T Cell Therapy

CAR stands for Chimeric Antigen Receptor which is an artificially synthesized receptor which mimics the receptor for T cells. This is very sensitive to the cancerous cells present on the surface of the MHC. This basically targets the B- cell lymphoma till date. CAR is responsible to trigger the antiapoptotic function of the primary T cell.

CAR considers the following steps: (Fig. 3)

- Collection of T cells: The T cells are withdrawn from a body part and made to flow through the apheresis machine which filters the T cells and sends back the remaining blood back to the body through another tube.
- Modification of the cells: The CAR is engineered in the lab and made to proliferate.
- Infusion of engineered CAR cell: The engineered cell is then transferred into the body post chemotherapy, so that it may not hinder with the currently existing pathogens, if any. [9,10].

Since, CAR therapy is still an ongoing assessment program, it certainly adds some side effects like nausea, fatigue, chills, vomiting, hypotension, tachycardia, arrhythmia, cardiac arrest, renal insufficiency and so on. The CAR therapy finds use in multiple myeloma, chronic lymphatic leukemia and other certain blood cancers. Since this is a newer process and not largely used, it comes with certain limitations like the infusion of CAR antigen involves a multidisciplinary approach with sophisticated instruments and should be according to the standards specified by Foundation for the Accreditation of Cellular Therapy (FACT). For this, the nursing staff shall be well trained and has met all the necessary training needed by the FACT. The work continues with the monitoring after the CAR antigen has been fused into the patient. A constant documentation based on neurological, toxicological studies shall be maintained in case of any obligations. Both the patients and the caregiver shall be equipped with necessary resources for any emergency situations. Patients are advised to monitor their body temperature from time to time and notify the clinical team for any discrepancy.[11]Hinge region are also taken into account that extends the binding to the transmembrane region. They provide the flexibility to overcome the steric hinderance observed at the time of infusion. It allows the targeted antigen for specific domain. [12].

A combination of all the above illustrated techniques is a boon to the society for the treatment of malignant carcinoma [13].




Fig 3: CAR Therapy

Conclusion

ACT is subdivided into TIL, TCR and CAR, all of which when considered in combination with each other can lead to be a boon in medical and pharmaceutical sciences. Since, this technology is just a matter in which both advancements are of their individual benefits. This technology, if cultured, will provide to be of great therapeutic help in oncogenic sciences. These combined challenges and technology require standardization; however, CAR T cells offer patients hope of advanced treatment. As the first therapy is already available in the market, there is potential for a specific and improved alternative becoming available in upcoming decades [14].

References

- [1] Rohaan MW, Wilgenhof S, Haanen JBAG. Adoptive cellular therapies: the current landscape. *Virchows Archiv* 2019;474:449–61. <https://doi.org/10.1007/s00428-018-2484-0>.
- [2] June CH, Riddell SR, Schumacher TN. Adoptive cellular therapy: A race to the finish line. *Sci Transl Med* 2015;7. <https://doi.org/10.1126/scitranslmed.aaa3643>.
- [3] June CH, Sadelain M. Chimeric Antigen Receptor Therapy. *New England Journal of Medicine* 2018;379:64–73. <https://doi.org/10.1056/NEJMra1706169>.
- [4] Yang Q-Y, Yang J, Wang Y-S. Current strategies to improve the safety of chimeric antigen receptor (CAR) modified T cells. *Immunol Lett* 2017;190:201–5. <https://doi.org/10.1016/j.imlet.2017.08.018>.
- [5] Chmielewski M, Abken H. TRUCKs: the fourth generation of CARs. *Expert Opin Biol Ther* 2015;15:1145–54. <https://doi.org/10.1517/14712598.2015.1046430>.
- [6] Vormittag P, Gunn R, Ghorashian S, Veraitch FS. A guide to manufacturing CAR T cell therapies. *Curr Opin Biotechnol* 2018;53:164–81. <https://doi.org/10.1016/j.copbio.2018.01.025>.
- [7] Zhu M, Wu B, Brandl C, Johnson J, Wolf A, Chow A, et al. Blinatumomab, a Bispecific T-cell Engager (BiTE®) for CD-19 Targeted Cancer Immunotherapy: Clinical Pharmacology and Its Implications. *Clin Pharmacokinet* 2016;55:1271–88. <https://doi.org/10.1007/s40262-016-0405-4>.
- [8] Tang X-Y, Sun Y, Zhang A, Hu G-L, Cao W, Wang D-H, et al. Third-generation CD28/4-1BB chimeric antigen receptor T cells for chemotherapy relapsed or refractory acute lymphoblastic leukaemia: a non-randomised, open-label phase I trial protocol. *BMJ Open* 2016;6:e013904. <https://doi.org/10.1136/bmjopen-2016-013904>.
- [9] Pasquini MC, Hu Z-H, Curran K, Laetsch T, Locke F, Rouse R, et al. Real-world evidence of tisagenlecleucel for pediatric acute lymphoblastic leukemia and non-Hodgkin lymphoma. *Blood Adv* 2020;4:5414–24. <https://doi.org/10.1182/bloodadvances.2020003092>.
- [10] Martyniszyn A, Krahl A-C, André MC, Hombach AA, Abken H. CD20-CD19 Bispecific CAR T Cells for the Treatment of B-Cell Malignancies. *Hum Gene Ther* 2017;28:1147–57. <https://doi.org/10.1089/hum.2017.126>.
- [11] Alexander M, Culos K, Roddy J, Shaw JR, Bachmeier C, Shigle TL, et al. Chimeric Antigen Receptor T Cell Therapy: A Comprehensive Review of Clinical Efficacy, Toxicity, and Best Practices for Outpatient Administration. *Transplant Cell Ther* 2021;27:558–70. <https://doi.org/10.1016/j.jctc.2021.01.014>.
- [12] di Stasi A, Tey S-K, Dotti G, Fujita Y, Kennedy-Nasser A, Martinez C, et al. Inducible Apoptosis as a Safety Switch for Adoptive Cell Therapy. *New England Journal of Medicine* 2011;365:1673–83. <https://doi.org/10.1056/NEJMoa1106152>.
- [13] McGuiirk J, Waller EK, Qayed M, Abhyankar S, Ericson S, Holman P, et al. Building blocks for institutional preparation of CTL019 delivery. *Cytotherapy* 2017;19:1015–24. <https://doi.org/10.1016/j.jcyt.2017.06.001>.
- [14] Galluzzi L, Martin P. CARs on a highway with roadblocks. *Oncoimmunology* 2017;6:e1388486. <https://doi.org/10.1080/2162402X.2017.1388486>.